Fertility treatments and breast cancer risk in Jewish Israeli BRCA mutation carriers


      To determine whether fertility treatments impact the risk of breast cancer in Jewish Israeli BRCA1/2 mutation carriers.


      Historical cohort study.


      University-affiliated tertiary medical center.


      A total of 1,824 Jewish Israeli BRCA1/2 mutation carriers from a single center were stratified into 1,492 (81.8%) carriers who were not treated for infertility and 332 (18.2%) carriers who underwent fertility treatment with clomiphene citrate (n = 134), gonadotropin (n = 119), in vitro fertilization (n = 183), or a combination of treatments (n = 89).



      Main Outcome Measure(s)

      Hazard ratios (HR) and 95% confidence intervals (CI) for the association of breast cancer with fertility treatment and other hormonal and reproductive variables.


      Breast cancer was diagnosed in 687 BRCA1/2 mutation carriers. Multivariate analysis, either of the whole group or stratified by each gene, showed no association between fertility treatment and breast cancer risk, regardless of the type of treatment (clomiphene citrate: HR 0.77, 95% CI 0.49–1.19; gonadotropin: HR 0.54, 95% CI 0.28–1.01; in vitro fertilization: HR 0.65, 95% CI 0.39–1.08; and combined treatments: HR 1.23, 95% CI 0.49–3.06). An increased breast cancer risk was associated with paternal origin of the mutation (HR 1.43, 95% CI 1.17–1.75) and use of oral contraceptives for >5 years (HR 1.62, 95% CI 1.27–2.06) in both BRCA1 and BRCA2 mutation carriers. Ovarian cancer risk was decreased with the use of any oral contraceptive (HR 0.61; 95% CI 0.46–0.82).


      Fertility treatment for BRCA1/2 mutation carriers is not associated with a discernible increase in breast cancer risk.
      El riesgo de los tratamientos de fertilidad y de cáncer de mama en portadoras de mutaciones BRCA en población judía israelí.


      determinar si los tratamientos de fertilidad afectan el riesgo de cáncer de mama en portadoras de la mutación BRCA1 / 2 judías israelíes.


      Estudio de cohorte histórica.


      Centro médico terciario afiliado a la universidad

      Paciente (s)

      Se ha estratificado un total de 1.824 judías israelíes portadoras de la mutación BRCA1 /2 de un solo centro en: 1.492 (81,8%) portadoras que no recibieron tratamiento por infertilidad y 332 (18,2%) portadoras que se sometieron a tratamiento de fertilidad con citrato de clomifeno (n = 134), gonadotropinas (n = 119), fertilización in vitro (n = 183) o una combinación de tratamientos (n = 89).

      Intervención (es)


      Principales medidas de resultado

      Cocientes de riesgo (HR) e intervalos de confianza (IC) del 95% para la asociación del cáncer de mama con los tratamientos de fertilidad y otras variables hormonales y reproductivas.

      Resultado (s)

      Se ha diagnosticado cáncer de mama en 687 portadoras de la mutación BRCA1 / 2. El análisis multivariado, ya sea del grupo completo o estratificado por cada gen, no mostró asociación entre el tratamiento de fertilidad y el riesgo de cáncer de mama, independientemente del tipo de tratamiento (clomifeno citrato: HR 0,77, IC del 95%: 0,49-1,19; gonadotropinas: HR 0,54, IC del 95%: 0,28 a 1,01; fertilización in vitro: HR 0,65, IC del 95%: 0,39-1,08; y tratamientos combinados: HR 1,23; IC del 95%: 0,49-3,06). Un mayor riesgo de cáncer de mama se asoció con el origen paterno de la mutación (HR 1,43; IC del 95%: 1,17–1,75) y el uso de anticonceptivos orales durante> 5 años (HR 1,62; IC del 95%: 1,27–2,06) tanto en las portadoras de la mutación BRCA1 como de BRCA2. El riesgo de cáncer de ovario se redujo con el uso de cualquier anticonceptivo oral (HR 0,61; IC del 95%: 0,46 a 0,82).

      Conclusión (es)

      El tratamiento de fertilidad para las portadoras de la mutación BRCA1 / 2 no se asocia con un aumento perceptible del riesgo de cáncer de mama.

      Key Words

      To read this article in full you will need to make a payment


        • Antoniou A.
        • Pharoah P.D.
        • Narod S.
        • Risch H.A.
        • Eyfjord J.E.
        • Hopper J.L.
        • et al.
        Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies.
        Am J Hum Genet. 2003; 72: 1117-1130
        • Kuchenbaecker K.B.
        • Hopper J.L.
        • Barnes D.R.
        • Phillips K.A.
        • Mooij T.M.
        • Roos-Blom M.J.
        • et al.
        Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
        J Am Med Assoc. 2017; 317: 2402-2416
        • Liu R.
        • Kitamura Y.
        • Kitamura T.
        • Sobue T.
        • Sado J.
        • Sugawara Y.
        • et al.
        Reproductive and lifestyle factors related to breast cancer among Japanese women: an observational cohort study.
        Medicine. 2019; 98e18315
        • Lambertini M.
        • Santoro L.
        • Del Mastro L.
        • Nguyen B.
        • Livraghi L.
        • Ugolini D.
        • et al.
        Reproductive behaviors and risk of developing breast cancer according to tumor subtype: a systematic review and meta-analysis of epidemiological studies.
        Cancer Treat Rev. 2016; 49: 65-76
        • Gennari A.
        • Costa M.
        • Puntoni M.
        • Paleari L.
        • De Censi A.
        • Sormani M.P.
        • et al.
        Breast cancer incidence after hormonal treatments for infertility: systematic review and meta-analysis of population-based studies.
        Breast Cancer Res Treat. 2015; 150: 405-413
        • van den Belt-Dusebout A.W.
        • Spaan M.
        • Lambalk C.B.
        • Kortman M.
        • Laven J.S.
        • van Santbrink E.J.
        • et al.
        Ovarian stimulation for in vitro fertilization and long-term risk of breast cancer.
        J Am Med Assoc. 2016; 316: 300-312
        • Sergentanis T.N.
        • Diamantaras A.A.
        • Perlepe C.
        • Kanavidis P.
        • Skalkidou A.
        • Petridou E.T.
        IVF and breast cancer: a systematic review and meta-analysis.
        Hum Reprod Update. 2014; 20: 106-123
        • Kroener L.
        • Dumesic D.
        • Al-Safi Z.
        Use of fertility medications and cancer risk: a review and update.
        Curr Opin Obstet Gynecol. 2017; 29: 195-201
        • Kotsopoulos J.
        • Librach C.L.
        • Lubinski J.
        • Gronwald J.
        • Kim-Sing C.
        • Ghadirian P.
        • et al.
        Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study.
        Cancer Causes Control. 2008; 19: 1111-1119
        • Derks-Smeets I.A.P.
        • Schrijver L.H.
        • de Die-Smulders C.E.M.
        • Tjan-Heijnen V.C.G.
        • van Golde R.J.T.
        • Smits L.J.
        • et al.
        Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers.
        Br J Cancer. 2018; 119: 357-363
        • Huber D.
        • Seitz S.
        • Kast K.
        • Emons G.
        • Ortmann O.
        Use of fertility treatments in BRCA1/2 mutation carriers and risk for ovarian and breast cancer: a systematic review.
        Arch Gynecol Obstet. 2020; 302: 715-720
        • Laitman Y.
        • Borsthein R.T.
        • Stoppa-Lyonnet D.
        • Dagan E.
        • Castera L.
        • Goislard M.
        • et al.
        Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel.
        Breast Cancer Res Treat. 2011; 127: 489-495
        • Kauff N.D.
        Society of Gynecologic Oncologists Clinical Practice Committee statement on prophylactic salpingo-oophorectomy.
        Gynecol Oncol. 2005; 98: 179-181
        • Walker J.L.
        • Powell C.B.
        • Chen L.M.
        • Carter J.
        • Bae Jump V.L.
        • Parker L.P.
        • et al.
        Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer.
        Cancer. 2015; 121: 2108-2120
        • Oktay K.
        • Kim J.Y.
        • Barad D.
        • Babayev S.N.
        Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks.
        J Clin Oncol. 2010; 28: 240-244
        • Wang E.T.
        • Pisarska M.D.
        • Bresee C.
        • Chen Y.D.
        • Lester J.
        • Afshar Y.
        • et al.
        BRCA1 germline mutations may be associated with reduced ovarian reserve.
        Fertil Steril. 2014; 102: 1723-1728
        • Ben-Aharon I.
        • Levi M.
        • Margel D.
        • Yerushalmi R.
        • Rizel S.
        • Perry S.
        • et al.
        Premature ovarian aging in BRCA carriers: a prototype of systemic precocious aging?.
        Oncotarget. 2018; 9: 15931-15941
        • Gietel-Habets J.J.
        • de Die-Smulders C.E.
        • Derks-Smeets I.A.
        • Tibben A.
        • Tjan-Heijnen V.C.
        • van Golde R.
        • et al.
        Awareness and attitude regarding reproductive options of persons carrying a BRCA mutation and their partners.
        Hum Reprod. 2017; 32: 588-597
        • Toss A.
        • Grandi G.
        • Cagnacci A.
        • Marcheselli L.
        • Pavesi S.
        • De Matteis E.
        • et al.
        The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation.
        Oncotarget. 2017; 8: 9144-9154
        • Park B.
        • Hopper J.L.
        • Win A.K.
        • Dowty J.G.
        • Sung H.K.
        • Ahn C.
        • et al.
        Reproductive factors as risk modifiers of breast cancer in BRCA mutation carriers and high-risk non-carriers.
        Oncotarget. 2017; 8: 102110-102118
        • Pasanisi P.
        • Hédelin G.
        • Berrino J.
        • Chang-Claude J.
        • Hermann S.
        • Steel M.
        • et al.
        Oral contraceptive use and BRCA penetrance: a case-only study.
        Cancer Epidemiol Biomarkers Prev. 2009; 18: 2107-2113
        • Jernström H.
        • Loman N.
        • Johannsson O.T.
        • Borg A.
        • Olsson H.
        Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing.
        Eur J Cancer. 2005; 41: 2312-2320
        • Ritte R.
        • Tikk K.
        • Lukanova A.
        • Tjønneland A.
        • Olsen A.
        • Overvad K.
        • et al.
        Reproductive factors and risk of hormone receptor positive and negative breast cancer: a cohort study.
        BMC Cancer. 2013; 13: 584
        • Iodice S.
        • Barile M.
        • Rotmensz N.
        • Feroce I.
        • Bonanni B.
        • Radice P.
        • et al.
        Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis.
        Eur J Cancer. 2010; 46: 2275-2284
        • Bhothisuwan K.
        Contraception and breast cancer.
        J Med Assoc Thai. 2004; 87: S167-S168
        • Cibula D.
        • Zikan M.
        • Dusek L.
        • Majek O.
        Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.
        Expert Rev Anticancer Ther. 2011; 11: 1197-1207
        • Moorman P.G.
        • Havrilesky L.J.
        • Gierisch J.M.
        • Coeytaux R.R.
        • Lowery W.J.
        • Peragallo Urrutia R.
        • et al.
        Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.
        J Clin Oncol. 2013; 31: 4188-4198
        • Ellberg C.
        • Jernström H.
        • Broberg P.
        • Borg Å.
        • Olsson H.
        Impact of a paternal origin of germline BRCA1/2 mutations on the age at breast and ovarian cancer diagnosis in a Southern Swedish cohort.
        Genes Chromosomes Cancer. 2015; 54: 39-50
        • Senst N.
        • Llacuachaqui M.
        • Lubinski J.
        • Lynch H.
        • Armel S.
        • Neuhausen S.
        • et al.
        Parental origin of mutation and the risk of breast cancer in a prospective study of women with a BRCA1 or BRCA2 mutation.
        Clin Genet. 2013; 84: 43-46
        • Vos J.R.
        • Oosterwijk J.C.
        • Aalfs C.M.
        • Rookus M.A.
        • Adank M.A.
        • van der Hout A.H.
        • et al.
        Bias explains most of the parent-of-origin effect on breast cancer risk in BRCA1/2 mutation carriers.
        Cancer Epidemiol Biomarkers Prev. 2016; 25: 1251-1258